CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2015 |
Jun. 30, 2014 |
Jun. 30, 2015 |
Jun. 30, 2014 |
|
| OPERATING EXPENSES | ||||
| General and administrative | $ 552 | $ 222 | $ 1,024 | $ 674 |
| Research and development | 283 | 1,172 | 633 | 1,802 |
| Total operating expenses | 835 | 1,394 | 1,657 | 2,476 |
| Interest and other expenses (income), net | (47) | (3) | 9 | (63) |
| Loss from operations before taxes | 788 | 1,391 | 1,666 | 2,413 |
| Income tax benefit | (36) | 0 | (198) | 0 |
| NET LOSS | 752 | 1,391 | 1,468 | 2,413 |
| Less: Net Loss attributable to the noncontrolling interest | 0 | 0 | 0 | 0 |
| Net Loss attributable to Capstone Therapeutics Corp. stockholders | $ 752 | $ 1,391 | $ 1,468 | $ 2,413 |
| Per Share Information: | ||||
| Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share) | $ 0.02 | $ 0.03 | $ 0.04 | $ 0.06 |
| Basic and diluted shares outstanding (in shares) | 40,885 | 40,885 | 40,885 | 40,885 |